Sartorius Stedim Biotech signed an agreement to acquire Polyplus-transfection SA from investors ARCHIMED and Warburg Pincus LLC and others for ?2.4 billion on March 31, 2023. Sartorius AG will receive a bridge loan facility from J.P. Morgan for a transitional period to finance the transaction. Sartorius intends to refinance this loan with long-term financing instruments which might also include an equity component. The proposed transaction is subject to customary conditions, including completion of the information and consultation of the works' council and approval by regulatory authorities and is expected to close during the third quarter of 2023. Jefferies LLC acted as financial advisor and Adrian Maguire, Laurent Victor-Michel, Eric J. Wedel, Sonia Bouaffassa, Marin Boney, Matthew Sinclair-Thomson, Peter Abbott, Paula Riedel, Stefan Arnold-Soulby and Ben Steadman of Kirkland & Ellis LLP provided legal counsel to Polyplus and its shareholders. William Blair acted as financial advisor and Milbank LLP and Jeantet provided legal counsel to Sartorius. Laurent Victor-Michel, Nadine Gelli and Sofia Bouaffassa of Kirkland & Ellis LLP acted as legal advisors for ARCHIMED and Warburg Pincus LLC. PWC provided the financial due diligence to ArchiMed SAS and Warburg Pincus LLC. Thomas Neubaum of Allen & Overy acted as legal advisor to Sartorius.

Sartorius Stedim Biotech completed the acquisition of Polyplus-transfection SA from investors ARCHIMED and Warburg Pincus LLC and others on July 18, 2023. The transaction completed after receiving the required regulatory approvals. As of September 7, 2023, Sartorius completes placement of bonds with a volume of ?3 billion. The company plans to use the net proceeds from the bond issue to repay the bridge financing for the acquisition of Polyplus and for general corporate purposes.